DDW 2016: Stem Cells Help Heal Perianal Fistulas, Increasing Rates of Colorectal Cancer in Younger Individuals, and Agents Effective Against HCV Genotypes 1–6

Researchers reported important findings on a variety of gastrointestinal and hepatic disorders at Digestive Disease Week in San Diego. – A small, phase 1 study reported that a bioprosthesis plug soaked in autologous mesenchymal stem cells helped heal refractory perianal fistulas that commonly occur in patients with Crohn’s disease. Amy

Read more
  • Does a PNPLA3 Polymorphism Promote Fibrosis Progression in Patients with Hepatitis C?

Does a PNPLA3 Polymorphism Promote Fibrosis Progression in Patients with Hepatitis C?

A single nucleotide polymorphism (SNP) in the patatin-like phospholipase domain containing 3 gene (PNPLA3) is associated with baseline level of fibrosis and its progression, but not development of hepatocellular carcinoma (HCC), in patients with hepatitis C virus (HCV) infection, researchers report in the February issue of Clinical Gastroenterology and Hepatology. Most

Read more
  • Gilead Sells Sofosbuvir to Egypt for About $10 per Pill

Gilead Sells Sofosbuvir to Egypt for About $10 per Pill

In Egypt, pharmaceutical companies are testing a complicated deal to sell hepatitis C drugs at a fraction of their usual cost while imposing tight restrictions intended to protect lucrative markets in the West. According to the New York Times, Gilead Sciences Inc. is selling its sofosbuvir to the Egyptian government

Read more
  • How Many Patients are Screened for HBV Infection Before Chemotherapy?

How Many Patients are Screened for HBV Infection Before Chemotherapy?

Only a small percentage of patients receiving chemotherapy are screened for hepatitis B virus (HBV) infection, although the proportion of patients screened has increased slightly over the past decade, researchers report in the May issue of Clinical Gastroenterology and Hepatology. Strategies are needed to ensure that patients receiving chemotherapy are

Read more

Cheap Allergy Drug Prevents HCV Infection of Hepatocytes

An over-the-counter allergy drug may be repurposed to treat patients with hepatitis C, researchers show. Chlorcyclizine, which costs about $0.50 a tablet, could offer a low-cost alternative or addition to treatment for patients with hepatitis C virus (HCV) infection. Direct-acting antiviral therapies can cure hepatitis C, but their high cost—which

Read more
  • Hepatitis C Drugs Might be Cost Effective but Demand Could Bust the Healthcare Bank

Hepatitis C Drugs Might be Cost Effective but Demand Could Bust the Healthcare Bank

Treating patients with hepatitis C virus (HCV) infection using recently approved direct-acting agents can be cost effective, but will also have substantial effects on healthcare costs, researchers show. Recently approved drugs cure more than 90% of patients with hepatitis C and could make the liver disease rare in the United

Read more
  • Who is on the Liver Transplant Waitlist?

Who is on the Liver Transplant Waitlist?

The number of adults with nonalcoholic steatohepatitis (NASH) waiting for liver transplants has almost tripled in the last 10 years, researchers report in the March issue of Gastroenterology. NASH is now the second leading liver disease of adults awaiting liver transplantation in the United States, the researchers found. The prevalence of nonalcoholic fatty

Read more

Mapping HCV Infection in the Liver

Using single-cell laser capture and high-resolution analysis, researchers show that hepatitis C virus (HCV) infects hepatocytes in the human liver in nonrandom clusters, whereas expression of anti-viral molecules is scattered among hepatocytes. The findings are presented in the December issue of Gastroenterology. HCV predominantly infects hepatocytes, but most hepatocytes in

Read more

Can We Treat Chronic HCV Infection Without Interferon?

A potent combination of 2 drugs that directly target the hepatitis C virus (HCV) is effective in patients with chronic infection, and doesn’t require interferon therapy, according to an article in the December issue of Gastroenterology. Patients infected with HCV genotype-1 are usually treated with peginterferon and ribavirin, but approximately

Read more